Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension

References

• Alphs L, Fu DJ, Turkoz I. (2016). Paliperidone for the treatment of schizoaffective disorder. Expert Opin Pharmacother 17:871–83.
   PubMed Web of Science ®Google Scholar
• Boom S, Talluri K, Janssens L, et al. (2009). Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 49:1318–30.
   PubMed Web of Science ®Google Scholar
• Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. (2014). The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 4:198–219.
   PubMedGoogle Scholar
• Canuso CM, Battisti WP. (2010). Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. Expert Opin Pharmacother 11:2557–67.
   PubMed Web of Science ®Google Scholar
• Cleton A, Rossenu S, Crauwels H, et al. (2014). A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular Injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. J Clin Pharmacol 54:1048–57.
   PubMed Web of Science ®Google Scholar
• Corena-McLeod M. (2015). Comparative pharmacology of risperidone and paliperidone. Drugs R D 15:163–74.
   PubMed Web of Science ®Google Scholar
• Darville N, van Heerden M, Mariën D, et al. (2016a). The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension. J Control Release 230:95–108.
   PubMed Web of Science ®Google Scholar
• Darville N, van Heerden M, Erkens T, et al. (2016b). Modeling the time course of the tissue responses to intramuscular long-acting paliperidone palmitate nano-/microcrystals and polystyrene microspheres in the rat. Toxicol Pathol 44:189–210.
   PubMed Web of Science ®Google Scholar
• Darville N, van Heerden M, Vynckier A, et al. (2014). Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats. J Pharm Sci 103:2072–87.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez A, Catalán R, Penadés R, et al. (2015). Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review. Patient Prefer Adherence 9:695–706.
   PubMedGoogle Scholar
• Greenberg WM, Citrome L. (2015). Paliperidone palmitate for schizoaffective disorder: a review of the clinical evidence. Neurol Ther 4:81–9.
   PubMed Web of Science ®Google Scholar
• INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable suspension for intramuscular use, approved in USA (2006). Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf [last accessed March 10, 2018].
   Google Scholar
• Jones A, Jones M. (2016). Reviewing depot injection efficacy in the treatment of schizophrenia. Nurs Stand 30:50–9.
   PubMedGoogle Scholar
• Kim S, Solari H, Weiden PJ, Bishop JR. (2012). Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. Patient Prefer Adherence 6:533–45.
   PubMed Web of Science ®Google Scholar
• Leng D, Chen H, Li G, et al. (2014). Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size. Int J Pharm 472:380–5.
   PubMed Web of Science ®Google Scholar
• Morrissette DA, Stahl SM. (2012). Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. CNS Spectr 17:10–21.
   PubMed Web of Science ®Google Scholar
• Nanaki S, Tseklima M, Terzopoulou Z, et al. (2017). Use of mesoporous cellular foam (MCF) in preparation of polymeric microspheres for long acting injectable release formulations of paliperidone antipsychotic drug. Eur J Pharm Biopharm 117:77–90.
   PubMed Web of Science ®Google Scholar
• NDA22264. (2009). Clinical Pharmacology and biopharmaceutics review(s): paliperidone palmitate. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022264s000clinpharmr.pdf [last accessed March 10, 2018].
   Google Scholar
• Novalbos J, López-Rodríguez R, Román M, et al. (2010). Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol 30:504–11.
   PubMed Web of Science ®Google Scholar
• Pani L, Marchese G. (2009). Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv 6:319–31.
   PubMed Web of Science ®Google Scholar
• Prajapati AR, Wilson J, Maidment I. (2016). Efficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysis. BMJ Open 6:e010237.
   PubMed Web of Science ®Google Scholar
• Roberto P, Brandt N, Onukwugha E, et al. (2017). Adherence to antipsychotic therapy: association with hospitalization and medicare spending among part D enrolees with schizophrenia. Psychiatr Serv 68:1185–8.
   PubMed Web of Science ®Google Scholar
• Rossenu S, Cleton A, Hough D, et al. (2015). Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Clin Pharmacol Drug Dev 4:270–8.
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Grunze H, Leucht S, Vita A. (2015). Long-acting injection antipsychotic medications in the management of schizophrenia. Evidence-Based Psychiatric Care 1:27–36.
   Google Scholar
• Samtani MN, Vermeulen A, Stuyckens K. (2009). Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 48:585–600.
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2009). Dodging matrix effects in liquid chromatography tandem mass spectrometric assays-compilation of key learnings and perspectives. Biomed Chromatogr 23:451–4.
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2014). Dilemma with matrix effect in bioanalysis-perspectives from bioavailability/bioequivalence studies for product registration? Drug Res (Stuttg) 64:335–6.
   PubMedGoogle Scholar
• Weiden PJ, Kim E, Bermak J, et al. (2017). Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidone. J Clin Psychiatry 78:e813–20.
   PubMed Web of Science ®Google Scholar
• Yang LP, Plosker GL. (2007). Paliperidone extended release. CNS Drugs 21:417–25.
   PubMed Web of Science ®Google Scholar
• Yoo HD, Lee SN, Kang HA, et al. (2011). Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br J Pharmacol 164:433–43.
   PubMed Web of Science ®Google Scholar